Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here?

Core Viewpoint - Hims & Hers (HIMS) stock surged nearly 50% after Novo Nordisk (NVO) dropped its lawsuit against the company, but caution is advised as the stock is still down about 37% from its year-to-date high [1][2]. Group 1: Stock Performance and Market Reaction - HIMS stock is expected to challenge its 50-day moving average, with a potential breakout above the $25 level likely to accelerate upward momentum [1]. - Despite the recent rally, Wall Street analysts suggest that the increase may be excessive, with a consensus rating of "Hold" and a mean target of $21.60 indicating a potential downside of about 3% from current levels [9][10]. Group 2: Business Model and Profitability Concerns - The agreement with Novo Nordisk indicates a shift for Hims & Hers from high-margin compounding to lower-margin distribution of branded GLP-1 drugs, which may negatively impact profit per customer and pressure margins over time [5]. - The availability of Wegovy on Amazon poses additional competition, as the e-commerce giant could leverage its logistics and user base to capture market share from Hims & Hers [6]. Group 3: Regulatory Challenges - Hims & Hers faces ongoing regulatory scrutiny, with the SEC investigating its public disclosures regarding compounded GLP-1 drugs, and the FDA maintaining restrictions on mass-marketed compounded drugs [7]. - Potential fines or mandated changes to business practices could hinder the company's ability to sustain recent gains, and the company does not currently pay a dividend [8].